drug
ceftobiprole medocaril
Marketedupdated 4mo agoby Innoviva Specialty Therapeutics Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying ceftobiprole medocaril
- phase3Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
- phase3Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
- —Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases
- phase1Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 3, 2029
~2.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
FDA exclusivities (2)
- Apr 3, 2034GAINGAIN Antibiotic (5y)
- Apr 3, 2029NCENew Chemical Entity (5y)2.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that